Go Pro
→ Shocking AI prediction from the “Billionaire Whisperer' (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$159.98
+0.2%		$166.11
$145.79
▼
$212.71
$247.59B0.253.14 million shs2.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$143.97
+5.4%		$92.35
$22.28
▼
$176.66
$54.54B1.133.44 million shs15.38 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+0.17%-1.63%+1.16%-10.52%-1.02%
Moderna, Inc. stock logo
MRNA
Moderna
+5.38%-1.09%+126.12%+188.46%+492.23%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$159.98
+0.2%		$166.11
$145.79
▼
$212.71
$247.59B0.253.14 million shs2.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$143.97
+5.4%		$92.35
$22.28
▼
$176.66
$54.54B1.133.44 million shs15.38 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+0.17%-1.63%+1.16%-10.52%-1.02%
Moderna, Inc. stock logo
MRNA
Moderna
+5.38%-1.09%+126.12%+188.46%+492.23%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.76
Moderate Buy$206.6729.19% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-46.71% Downside

Current Analyst Ratings Breakdown

Latest MRNA and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/8/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$180.00
8/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Peer Perform
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$61.37B4.04$12.95 per share12.35$31.41 per share5.09
Moderna, Inc. stock logo
MRNA
Moderna
$2.21B26.01N/AN/A$22.14 per share6.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6923.9115.191.3517.02%31.45%13.20%10/30/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest MRNA and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$1.61$15.44 billion$15.38 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.71%+2.30%64.87%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Promising Biotech Stocks To Keep An Eye On - September 12th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-to-keep-an-eye-on-september-12th-2026-09-12/
California State Teachers Retirement System Buys 27,274,128 Shares of Moderna, Inc. $MRNA
September 12 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-27274128-shares-of-moderna-inc-mrna-2026-09-12/
How Cathie Wood's fund gave us a back door to Moderna's breakthrough
September 11 at 6:53 PM  |  msn.comhttps://www.msn.com/en-us/news/other/how-cathie-woods-fund-gave-us-a-back-door-to-modernas-breakthrough/ar-AA2c2Klx
Healthcare Stocks To Keep An Eye On - September 11th
September 11 at 2:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-healthcare-stocks-to-keep-an-eye-on-september-11th-2026-09-11/
Moderna (NASDAQ:MRNA) Shares Up 6.7% - Should You Buy?
September 11 at 12:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moderna-nasdaq-mrna-shares-up-67-should-you-buy-2026-09-11/
Best Biotech Stocks To Watch Now - September 11th
September 11 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-best-biotech-stocks-to-watch-now-september-11th-2026-09-11/
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
September 11 at 11:56 AM  |  247wallst.comhttps://247wallst.com/investing/2026/09/11/moderna-rallies-8-on-2026-melt-up-momentum-even-while-biontech-and-merck-stay-flat/?utm_source=snapi
Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA
September 11 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-reduces-stock-holdings-in-moderna-inc-mrna-2026-09-11/
Rep. Maria Elvira Salazar Sells Moderna, Inc. (NASDAQ:MRNA) Stock
September 11 at 2:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-rep-maria-elvira-salazar-sells-moderna-inc-nasdaq-mrna-stock-2026-09-11/
Rep. Maria Elvira Salazar Acquires Shares of Moderna, Inc. (NASDAQ:MRNA)
September 11 at 2:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-rep-maria-elvira-salazar-acquires-shares-of-moderna-inc-nasdaq-mrna-2026-09-11/
Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions
September 10 at 7:03 PM  |  benzinga.comhttps://www.benzinga.com/news/politics/26/09/61730264/congresswoman-bets-on-elon-musk-warren-buffett-heres-the-latest-stock-transactions?utm_source=snapi
mRNA cancer vaccines’ biggest barriers to market
September 10 at 1:16 PM  |  pharmavoice.comP
Best Biotech Stocks To Add to Your Watchlist - September 10th
September 10 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-best-biotech-stocks-to-add-to-your-watchlist-september-10th-2026-09-10/
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $4.44 Million in Moderna, Inc. $MRNA
September 10 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-invests-444-million-in-moderna-inc-mrna-2026-09-10/
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
September 9 at 10:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-set-3-near-term-155826180.html
Biotech Stocks To Consider - September 9th
September 9 at 12:04 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-consider-september-9th-2026-09-09/
AI & Robotics in 2026: 16 Recent Developments for Investors
September 9 at 11:34 AM  |  etftrends.comE
Promising Biotech Stocks To Consider - September 7th
September 9 at 1:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31011657
What to know about the new mRNA flu vaccine
September 8, 2026  |  hub.jhu.eduH
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
September 8, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986549/mrna-stock-soars-143-in-a-month-time-to-buy-hold-or-sell?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2986549
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mrna-stock-soars-143-month-144000490.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Astrazeneca stock logo

Astrazeneca NYSE:AZN

$159.98 +0.34 (+0.21%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$156.10 -3.87 (-2.42%)
As of 09/11/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Moderna stock logo

Moderna NASDAQ:MRNA

$143.97 +7.35 (+5.38%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$144.62 +0.65 (+0.45%)
As of 09/11/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas